EU blocks $7.1bn takeover of cancer detection company
Illumina bid would have “stifled innovation” | EU said Illumina was the "unrivalled supplier” of next-generation sequencing systems for genetic and genomic analysis.
Vidal steps up scrutiny of Fintiv rule-based decisions
Mylan and Edwards Lifesciences argue that the controversial rule safeguards poor-quality patents | US v Arthrex conferred increased authority to Vidal over PTAB decisions.
USPTO unveils tool to access key FDA data
Web page reveals information concerning patent term extension applications | President Joe Biden urged collaboration between USPTO and FDA.
Big pharma firm hits back in COVID-19 tech dispute
CureVac accuses Pfizer and its German partner of infringing patented tech in landmark COVID-19 treatment | The pharma giant says that the patents are invalid
Novo Nordisk makes $1.1bn bid for biopharma company
Massachusetts-based target company specialises in rare blood disorders | Deal gives Novo Nordisk access to lead development candidate, etavopivat.
Court delivers split ruling in lung drug dispute
Lengthy opinion invalidated plaintiff’s patent but ruled that defendant’s would still infringe | Patents at issue related to treatment for high blood pressure in the lungs.
Carpmaels & Ransford adds partner with UPC focus
New partner brings pharma and chemistry focus, and boosts the European firm’s Unified Patent Court team.
AltaThera hits competitor with trade secret suit
Suit claims a contractor used AltaThera secrets to launch a rival heart arrhythmia drug | Chicago-based company wants the court to add its founder as co-inventor on patent.
O’Melveny recruits IP litigator for New York office
O’Melveny has hired life sciences patent litigator Gregory Morris for its New York office as a partner in its IP and technology practice group.
Novartis sued over blockbuster heart failure drug
Pharma company facing lawsuit from two universities | Dispute centres on therapeutically effective co-crystals patent.
